Cervical Cancer
Conditions
Keywords
Cervical Cancer, Propranolol, Betachron, Inderal, Beta blocker, Questionnaires, Surveys, Symptom inventory, Anxiety and depression survey, Pain inventory, Quality of life survey, Relaxation audio recording, MP3 player, Diary
Brief summary
The goal of this clinical research study is to learn how many patients with advanced, recurrent, incurable cervical cancer will complete questionnaires about symptoms, any anxiety, depression, and/or pain, and the quality of their lives. Researchers also want to learn how many of these patients will complete a study treatment of propranolol hydrochloride and relaxation and guided imagery sessions. Researchers also want to learn if and how propranolol hydrochloride and relaxation and guided imagery may affect cancer symptoms and any anxiety, depression, and/or pain, and quality of life. Propranolol hydrochloride is designed to block certain chemicals that affect the heart. Relaxation and guided imagery sessions are a form of relaxing meditation that involves tensing and relaxing various parts of your body from your feet to your head. In the guided imagery portion, you listen to recordings that are designed to help with calmness, control, and decreasing stress.
Detailed description
Study Therapy Administration: If you are found to be eligible to take part in this study, you will take propranolol by mouth 2 times a day. While taking the drug, you should continue to check your blood pressure daily with your own personal blood pressure machine, at your local pharmacy, or in the clinic. If you are personally monitoring your blood pressure, you should contact the research nurse if the systolic blood pressure (SBP - the higher number) is less than 110, or if the diastolic (DBP - the lower number) is less than 50 (or your heart rate is 50-60 and you show symptoms at 2 different timepoints 24 hours apart). The study doctor may decide to lower or raise your dose of study drug during the study based on your heart rate and/or blood pressure measurements. You will fill out a pill diary to write down the doses of propranolol that you take each day. For the relaxation and guided imagery sessions, you will be given an MP3 player with an audio recording that you should listen to 2 times a week for up to 4 months (or longer if you choose). The study staff will talk to you about how to complete the sessions. You will fill out a relaxation diary to write down whether you were able to complete the sessions and whether you had any difficulties with it, such as distractions. You should bring both diaries to the clinic at each visit. Study Visits: At Month 1: * Your vital signs will be measured. * You will be asked about any side effects you may have had. At Months 2 and 4: * Your vital signs will be measured. * You will be asked about any side effects you may have had. Blood (about 5-6 teaspoons) will be drawn for routine tests and for testing on cytokines, RNA, and tumor markers. * You will complete the same questionnaires as at screening. * If the doctor thinks it is needed, you will have an EKG to check your heart function. * If you are an MD Anderson participant, the test to find out how many calories you need to have on a daily basis will be repeated. * At Month 2 only, if the doctor thinks it is needed, you will have a CT scan of the chest, abdomen, and pelvis to check the status of the disease. * At Month 4 only, any updates to your medical history will be recorded. You will have a physical exam. Length of Treatment: You may continue the study therapy for as long as the doctor thinks it is in your best interest. You will no longer be able to take the study therapy if the disease gets worse, if intolerable side effects occur, or if you are unable to follow study directions. Your active participation on the study will be over after the last visit. The study staff will continue checking your medical record from then on to see how you are doing. This is an investigational study. Propranolol is FDA approved and commercially available to treat certain heart and blood pressure problems, anxiety, migraines, and tremors. Its use in this study is investigational. Up to 20 participants will be enrolled in this multicenter study. Up to 5 will be enrolled at the Harris Health System. Up to 10 will be enrolled at MD Anderson.
Interventions
DRUGPropranolol
Starting dose: 20 mg is taken by mouth twice a day (40 mg/day).
BEHAVIORALDiary
Patients record study medication taken each day in a pill diary. Relaxation diary completed after listening to audio sessions twice a week.
BEHAVIORALRelaxation Audio Recording
Patient given an MP3 player with an audio recording to listen to 2 times a week for up to 4 months. The recording lasts 20 minutes.
BEHAVIORALQuestionnaires
Questionnaires completed at baseline, 2 months, and 4 months.
Sponsors
M.D. Anderson Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Proven recurrent cervical cancer of any histology not eligible for curative radiotherapy or surgery. 2. Failed chemotherapy for first recurrence (excluding chemotherapy with concurrent irradiation) or refractory to first line systemic therapy. 3. Measurable or non-measurable disease 4. Unlimited prior therapies
Exclusion criteria
1. Patients whose disease may be cured by surgery or radiotherapy. 2. Contraindication to use of a beta-blocker.(uncontrolled DM, COPD-unstable, Bradycardia \<50 BPM) 3. Already receiving a beta-blocker. 4. Performance status \>3. Must have had treatment for first line recurrence 5. Prior radiation therapy for localized cancer of the breast, head and neck, or skin is permitted provided that it was completed more than 3 years prior to registration, and the patient remains free of recurrent or metastatic disease. 6. With the exception of non-melanoma skin cancer and other specific malignancies as noted above, patients with other invasive malignancies who had (or have) any evidence of the other cancer present within the last five years or whose previous cancer treatment contraindicates this protocol therapy are excluded. 7. Use of systemic glucocorticoids such as Prednisone or Decadron in the last month for greater than one week 8. Inability to accurately answer questions (e.g. dementia, brain metastases) or speak English or Spanish. 9. Cirrhosis of the liver 10. Patients under the age of 18 11. History of comorbid conditions: Addison's disease, autoimmune hepatitis, hepatitis B, hepatitis C, AIDS or HIV, lupus erythematosus, mixed connective tissue disease, rheumatoid arthritis. 12. Hypersensitivity to propranolol, or beta-blockers 13. Uncompensated congestive heart failure 14. Cardiogenic shock 15. Severe sinus bradycardia; heart block, second or third degree or sick sinus syndrome (if no artificial pacemaker present) 16. Severe hyperactive airway disease (chronic obstructive pulmonary disease, asthma) 17. Any patients on Avastin or any other anti-angiogenic drugs. 18. Patients with brittle diabetes mellitus (DM). Brittle diabetes mellitus is a type of diabetes when a person's blood glucose (sugar) level often swings quickly from high to low and from low to high. Also called unstable diabetes or labile diabetes. 19. Patients participating in or who plan to participate in other treatment trials during the course of this study. 20. Patients actively using cocaine 21. Cannot be receiving any other active neoplastic treatment during 4 months of study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Patients Completing Symptom Inventories | 2 months | To determine the proportion of patients completing symptom inventory, anxiety and depression survey, pain inventory, and quality of life surveys (MDASI, HADS\< BPI, FACT-Cx). |
Countries
United States
Participant flow
Recruitment details
Recruitment period: 09/2013 until 02/2015. All the recruitment was done in a medical clinic setting.
Pre-assignment details
6 patients were registered on this study but only 5 received treatment - 1 patient signed consent but did not receive any treatment on study due to physician decision after consultation with cardiology
Participants by arm
| Arm | Count |
|---|---|
| Propranolol + Relaxation/Guided Imagery A starting dose of propranolol 20 mg is taken by mouth twice a day (40 mg/day). If patient tolerates the initial dose (no hypotension or bradycardia), dose increased to 40 mg by mouth twice a day at start of second month of therapy. Patients record study medication taken each day in a pill diary. Patient given an MP3 player with an audio recording to listen to 2 times a week for up to 4 months. The recording lasts 20 minutes. Relaxation diary completed stating whether patient was able to complete the sessions and whether they had any difficulties with it. | 6 |
| Total | 6 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Death | 1 |
| Overall Study | Physician Decision | 1 |
| Overall Study | Withdrawal by Subject | 1 |
Baseline characteristics
| Characteristic | Propranolol + Relaxation/Guided Imagery |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 1 Participants |
| Age, Categorical Between 18 and 65 years | 5 Participants |
| Age, Continuous | 50 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 3 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 3 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 6 Participants |
| Region of Enrollment United States | 6 participants |
| Sex: Female, Male Female | 6 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 1 / 5 |
| other Total, other adverse events | 2 / 5 |
| serious Total, serious adverse events | 1 / 5 |
Outcome results
Primary
Proportion of Patients Completing Symptom Inventories
To determine the proportion of patients completing symptom inventory, anxiety and depression survey, pain inventory, and quality of life surveys (MDASI, HADS\< BPI, FACT-Cx).
Time frame: 2 months
Population: data were not collected due to protocol terminated early.